Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.
McKenna SP, Whalley D, Doward LC. No SF-36 please – we're British!. Proc Br Psychol Soc. 2001;9(1):70.
McKenna SP, Doward LC, Van Assche D. Diabetic foot ulcers: a patients' perspective. Proc Br Psychol Soc. 2001;9(1):70.
Whalley D, Doward LC, McKenna SP. Urogenital atrophy: an accepted part of ageing? Proc Br Psychol Soc. 2001;9(1):78.
Doward LC, Whalley D, McKenna SP. Silent voices – hidden lives. Carer's perceptions of the impact of caring for a relative with Alzheimer's disease. Proc Br Psychol Soc. 2001;9(1):65.
Doward LC, Whalley D, McKenna SP. The development of the Alzheimer's Carers Quality of Life Instrument (ACQLI). Proc Br Psychol Soc. 2001;9(1):65.
Cook SA, Doward LC, McKenna SP, Erdman R, Niero M, Van Assche D. Venous leg ulcers – patient-reported impact on quality of life. Proc Br Psychol Soc. 2001;9(1):64.
Dewar Al, Doward LC, Whalley D, McKenna SP, Tennant A, Emery P. Impact of systemic lupus erythematosus (SLE) experienced from the patients' perspective. Proc Br Psychol Soc. 2001;9(1):64.